---
schema_version: "secwatch.filing_event.v1"
accession: "0001410098-26-000054"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2026-08-13T11:32:23+00:00"
generated_at: "2026-08-13T11:35:07.723858+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CorMedix Q2 revenue $101.9M, net income $26.0M; raises FY26 adjusted EBITDA guidance

## Summary
- Q2 2026 consolidated revenue of $101.9M; net income of $26.0M; adjusted EBITDA of $58.7M; diluted EPS $0.29.
- DefenCath net revenue $66.1M; acquired Melinta portfolio contributed $35.8M.
- FY26 revenue guidance maintained at $325-345M; adjusted EBITDA guidance raised to $125-140M.
- New multi-year DefenCath supply agreement with an LDO; now covers all top 5 U.S. dialysis providers.
- REZZAYO sNDA for prophylaxis of invasive fungal disease expected Q3 2026; FDA action anticipated H1 2027.

## SEC filing metadata
- accession: 0001410098-26-000054
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2026-08-13T11:32:23+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000141009826000054/0001410098-26-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000141009826000054/crmd-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001410098-26-000054
- JSON: https://secwatch.observer/filing/0001410098-26-000054.json
- Plain text: https://secwatch.observer/filing/0001410098-26-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.